Abbott Laboratories

Strategic Intent

Abbott Laboratories is a global healthcare leader that develops and manufactures a diversified portfolio of medical devices, diagnostic systems, nutritional products, and branded generic pharmaceuticals.

Key Market Signals

• 2026-01: Reported $44.3B annual revenue for FY2025, a 5.7% YoY increase.
• 2025-10: Won third bellwether trial in preterm infant formula litigation, mitigating some MDL risk.
• 2025-06: Published 2024 Global Sustainability Report showing 9% reduction in Scope 1 & 2 emissions.
• 2024-07: Landmark $495M verdict awarded against Abbott in first NEC infant formula trial.
• 2024-03: FDA clearance for next-generation protein-based diagnostic tests for concussion.

Financial Health

• Reported full-year 2025 revenue of $44.3 billion, representing a 5.7% increase over 2024 (Source: https://www.abbottinvestor.com/news-releases/news-release-details/abbott-reports-fourth-quarter-and-full-year-2025-results)
• Projected 2026 organic sales growth in the range of 6.5% to 7.5% (Source: https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2025-results-issues-2026-financial-outlook-302354123.html)
• Maintained a track record of 404+ consecutive quarterly dividends as of early 2025 (Source: https://www.tradingview.com/news/reuters.com,2025:newsml_RWN2631:0/)

Impact & Compliance

Legal & Risks

Abbott faces significant litigation risk from over 1,000 lawsuits related to its specialized infant formula (NEC), including a landmark $495 million jury verdict in July 2024, alongside an ongoing federal criminal investigation into its manufacturing facilities.

Forensic Audit — 1 findings

• Jury awarded $400 million in punitive damages specifically to punish 'misconduct' related to product risk transparency

Classifications

Proprietary Analysis